History

이미지

2018
~2015

2018
  • Signed an agreement with Sanofi Pasteur to license out cell-culture technology for producing cell culture-derived influenza vaccines
  • Established SK Bioscience.
2017
  • Launched Sky Zoster Inj., world’s second shingles vaccine
  • Signed an agreement with international organization PATH to develop and produce pediatric enteritis vaccine for developing countries
2016
  • Launched SKYCellflu Quadrivalent, world’s first quadrivalent cell culture-derived influenza vaccine
  • Gained approval for SKYPNEUMO, the first domestically produced PCV13 vaccine
2015
  • Launched SKYCellflu, Korea’s first trivalent cell culture-derived influenza vaccine
이미지

2014
~2012

2014
  • Established strategic partnership with Sanofi Pasteur for co-development of next-generation’s pneumococcal conjugate vaccine
  • Acquired KGMP for L HOUSE (Andong Vaccine Plant)
2013
  • Established partnership with IVI (International Vaccine Institute) to collaborate on the development of a new typhoid conjugate vaccine
2012
  • Construction of L HOUSE (Andong Vaccine Plant) completed
이미지
이미지

2009
~2001

2009
  • Out-licensed CSL’s NBP601 (hemophilia drug), Korea’s first bio-pharmaceutical drug
2006
  • Merged with Dongshin Pharm
2005
  • Established Vaccine R&D Center
2001
  • Acquired Dongshin Pharm (vaccine, blood products)